This effect, together with the decreased expression of fibromiRs and pro-inflammatory molecules (Figure 9), likely account for the potential anti-fibrotic, anti-inflammatory, and protective effects of PPARγ agonists in chronic kidney disease, which are highly relevant for the according clinical therapy. This evidence concerns the gene PPARG and chronic kidney disease.